General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 4% | news.google.com • |
Greenwich LifeSciences (NASDAQ:GLSI) Shares Down 4% | news.google.com • |
TOPS, SURG: The Top 5 Short Squeeze Stocks This Week | investorplace.com • |
GLSI, APRN: The Top 5 Short Squeeze Stocks to Watch This Week | investorplace.com • |
NRBO, FAZE: The Top 5 Short Squeeze Stocks to Watch This Week | investorplace.com • |
ATHX, PETS: The Top 5 Short Squeeze Stocks to Watch This Week | investorplace.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-27 | 2024-03 | -0.2 | N/A | N/A | N/A |
2024-04-15 | 2023-12 | 0 | -0.21 | N/A | N/A |
2023-10-19 | 2023-09 | -0.22 | -0.19 | 0.03 | 13.64% |
2023-10-19 | 2023-09 | -0.22 | N/A | N/A | N/A |
2023-08-21 | 2023-06 | -0.23 | N/A | N/A | N/A |
2023-08-21 | 2023-06 | -0.23 | -0.13 | 0.1 | 43.48% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-04-09 | HC Wainwright & Co. | Upgrade | Buy | |
2021-08-31 | HC Wainwright & Co. | Upgrade | Buy | |
2021-01-26 | Aegis Capital | Upgrade | Buy | |
2021-01-25 | Aegis Capital | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-04-24 | DAUGHERTY FRANK JOSEPH | Officer and Director | 90.12K | Purchase |
2022-01-20 | HALLOCK KENNETH | Director | 397.30K | Purchase |
2021-12-13 | MCWILLIAMS DAVID B | Director | 620.30K | Purchase |
2020-09-28 | PATEL KINNARY | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
2024-03-31 | PATEL SNEHAL | Chief Executive Officer | 5.35M | Purchase |
2020-11-19 | ROTHE ERIC | Director | 313.23K | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 282.21K | 2.72M | 2.20% |
2023-06-29 | Renaissance Technologies, LLC | 79.20K | 763.88K | 0.62% |
2023-06-29 | Ameriprise Financial, Inc. | 68.19K | 657.71K | 0.53% |
2023-06-29 | Blackrock Inc. | 57.58K | 555.31K | 0.45% |
2023-06-29 | Geode Capital Management, LLC | 39.93K | 385.15K | 0.31% |
2023-06-29 | Millennium Management Llc | 35.35K | 340.93K | 0.28% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 215.14K | 2.08M | 1.67% |
2023-06-29 | Vanguard Extended Market Index Fund | 54.75K | 528.08K | 0.43% |
2023-05-30 | Fidelity Extended Market Index Fund | 20.93K | 227.91K | 0.16% |
2023-08-30 | iShares Micro Cap ETF | 14.14K | 129.67K | 0.11% |
2023-05-30 | Fidelity NASDAQ Composite Index Fund | 7.22K | 78.63K | 0.06% |
2023-06-29 | Vanguard Balanced Index Fund | 6.06K | 58.49K | 0.05% |
$GLSI
STAFFORD, Texas--(BUSINESS WIRE)-- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that the Company will participate in the following interviews and conferences.
Today at 5:00 pm, the Company’s management team will be presenting two posters at the 2021 San Antonio Breast Cancer Symposium (SABCS) in person. The Company anticipates making the SABCS Phase IIb poster available on its website by the morning of December 9, exactly one year after the 2020 SABCS poster was published showing that no metastatic breast cancer recurrences were observed over 5 years of follow-up in HER2 positive patients who were fully treated. On December 9 at 2:20 pm ET, Snehal Patel, CEO of Greenwich LifeSciences, will appear as a featured guest in a live interview on TD Ameritrade Network's The Watch List with host Nicole Petallides to discuss the poster.
$GLSI ️ Idiot spotted!
$GLSI 10 more minutes to buy this share < 40$/share
There full report was posted on yahoo today
Only few days late
Wonder if this is going to pop today
What was that
What a shame! Shorts better hope there family or friends don’t get breast cancer!
Wow
I will hold and remain an investor of this company!
Not falling for this short attack
Dip and rip !!!
This will bounce
Holding no questions
Worst case catch this when it completes
Phase 3
Average 28
@ Stewart Smith, spot on. It is not a copy paste from previous results, it’s an update and confirms that the treatment works. How much simpler can one explain?
$GLSI today they proved again what a groundbreaking treatment they can provide to beat breast cancer. It’s beyond my comprehension that this proven record is not all over the news yet!!!